Alzheimer-kór: vizsgálatok itt: Magyarország
8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 15.. Ask the study team whether a trial fits you.
- 3. fázisBefejeződöttOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
- Where
- Budapest, Budapest XII, Gyongyos, Miskolc, Pécs, Szeged
- Életkor
- 55 év to 90 év
- People
- 1000 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00 - 2. fázisTaking peopleA Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- Where
- Gyongyos, Pécs
- Életkor
- 55 év to 90 év
- People
- 300 worldwide
- Run by
- MapLight Therapeutics
See details and how to joinNCT06887192 · EU 2024-519820-26-00 - 3. fázisNot yet taking people in MagyarországA Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- Where
- Budapest, Budapest III, Debrecen, Dunaujvaros, Gyongyos, Győr, Kalocsa
- Életkor
- 55 év to 90 év
- People
- 650 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00 - 2. fázisNot yet taking people in MagyarországAn Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
- Where
- Gyongyos, Pécs
- Életkor
- 55 év to 91 év
- People
- 210 worldwide
- Run by
- MapLight Therapeutics
See details and how to joinNCT07459660 · EU 2025-521757-16-00 - 3. fázisTaking peopleA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
- Where
- Budapest, Budapest III, Debrecen, Dunaujvaros, Gyongyos, Győr, Kalocsa
- Életkor
- 55 év to 90 év
- People
- 426 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07011745 · EU 2025-520612-34-00 - 3. fázisBefejeződöttA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Where
- Budapest, Budapest XII, Gyongyos, Pécs
- Életkor
- 55 év to 90 év
- People
- 406 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00 - 3. fázisBefejeződöttA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
- Where
- Budapest, Miskolc, Pécs
- Életkor
- 55 év to 90 év
- People
- 500 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06126224 · EU 2023-504416-16-00 - 1. fázisTaking peopleA clinical trial to learn how an investigational drug (MP-101) affects on the laboratory signs of the disease when given to Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease (AD) patients
- Where
- Kistarcsa
- Életkor
- 18 év and over
- People
- 40
- Run by
- Mitochon Pharmaceuticals Inc.
See details and how to join2023-507195-43-00